Ignite Creation Date:
2025-12-25 @ 4:13 AM
Ignite Modification Date:
2026-01-31 @ 6:06 AM
Study NCT ID:
NCT04267120
Status:
TERMINATED
Last Update Posted:
2025-03-21
First Post:
2020-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Sponsor:
Organization: